Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00051571 · ClinicalTrials.gov registry record · Phase 2

Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Seagen.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
9
Study locations

NCT00051571: Completed Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Seagen.

NCT00051571 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by Seagen. The registered enrollment target is 60 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (81% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00051571, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Seagen.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
9
Study locations

Study Summary

This randomized phase II clinical trial evaluates the combination of a monoclonal antibody-based drug (SGN-15) with a chemotherapeutic agent compared to chemotherapy given alone in patients with non-small cell lung cancer that has failed at least one prior systemic therapy. The objective of the study is to determine the safety and clinical benefit, as measured by tumor response and quality of life, to the combination regimen. Monoclonal antibody therapy has been used in other types of cancer to target therapy to the tumor, thereby allowing for the chemotherapeutic agent to have a lesser effect on normal, healthy tissue.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Docetaxel
  • DRUG SGN-15

Study Locations (9)

Florida

  • Florida Cancer Specialists - Fort Myers
  • Hematology Oncology Associates of the Treasure Coast - Port Saint Lucie

Oregon

  • Providence Health System - Portland
  • Kaiser Permanente - Portland

Washington

  • Virginia Mason Research Center - Seattle
  • Madigan Army Medical Center - Tacoma

California

  • UCLA Medical Center - Los Angeles

Connecticut

  • Bendheim Cancer Center - Greenwich

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 60 participants
Est. Completion 2003-10
Phase Phase 2
Seagen

84 total trials

What the finished NCT00051571 record still lists

NCT00051571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (81% lower).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.

NCT00051571 lists 9 locations in 6 states (Florida, Oregon, Washington).

Frequently Asked Questions

What is clinical trial NCT00051571 about?

NCT00051571 is a clinical study titled "Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma". This randomized phase II clinical trial evaluates the combination of a monoclonal antibody-based drug (SGN-15) with a chemotherapeutic agent compared to chemotherapy given alone in patients with non-small cell lung cancer that has failed at least one prior systemic therapy. The objective of the stud...

What is the current status of trial NCT00051571?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. Estimated completion is 2003-10.

What conditions does trial NCT00051571 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT00051571?

The interventions under investigation include: Docetaxel (DRUG), SGN-15 (DRUG).

Who is sponsoring clinical trial NCT00051571?

This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00051571 being conducted?

This trial has 9 study locations across California, Connecticut, Florida, Illinois, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00051571's enrollment target sits among peer trials

60 88th of 130 higher than 42 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Related registry views

Source: ClinicalTrials.gov NCT00051571, the US trial registry maintained by the National Library of Medicine. NCT00051571 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.